SILO

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Retrieved on: 
Wednesday, February 28, 2024

SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD).

Key Points: 
  • The purpose of the non-GLP small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials.
  • Data analysis demonstrated rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal.
  • “Non-GLP and GLP toxicology and safety pharmacology studies are required steps before seeking approval for our first-in-human clinical-stage trials of SPC-15,” said Eric Weisblum, CEO of Silo.
  • This is an exciting step forward for our Company as we advance our lead therapeutic, SPC-15.”

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Retrieved on: 
Wednesday, February 14, 2024

SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.

Key Points: 
  • A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.
  • In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (ketamine HCL) in two loadings, 20% and 40%.
  • “Implantable drug delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions,” said Eric Weisblum, CEO of Silo.
  • Silo believes that implantable drug delivery systems (IDDS) can offer a superior delivery alternative for sustained relief from chronic pain.

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Retrieved on: 
Thursday, February 1, 2024

SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced updates for its strategic 2024 focus for its clinical pipeline. The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.

Key Points: 
  • The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology.
  • A dose-ranging non GLP study of SPC-15 is in progress, with a final validation report expected in the first half of 2024.
  • As a self-administered treatment, SP-26 holds the potential to be the first at-home ketamine treatment approved for chronic pain management.
  • Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Retrieved on: 
Wednesday, January 24, 2024

SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals.

Key Points: 
  • Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety.
  • SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals.
  • Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety).
  • We look forward to updating our shareholders on the next steps and data needed to advance SPC-14 to a clinical study,” stated Eric Weisblum, Chief Executive Officer of Silo Pharma.

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Retrieved on: 
Thursday, January 4, 2024

ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.

Key Points: 
  • The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.
  • The six- to eight-week non-GLP study includes single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study.
  • In the first phase of the study, all of the animals appeared to tolerate the intranasal dosing procedure well, with minimal struggling and no sneezing observed.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, commented “There have been no adverse clinical observations reported to date for this study, which began in late November 2023 and will conclude in first quarter 2024.

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Retrieved on: 
Thursday, December 28, 2023

SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced an update on its dosage and time-release ketamine-loaded implant, designated as SP-26, which is being developed as a potential at-home pain relief treatment for fibromyalgia and other chronic pain conditions. In collaboration with Sever Pharma Solutions, Silo’s contract development and manufacturing partner, SP-26 is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.

Key Points: 
  • In collaboration with Sever Pharma Solutions, Silo’s contract development and manufacturing partner, SP-26 is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.
  • Silo intends to pursue the FDA’s streamlined 505(b)(2) pathway for approval of SP-26.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, commented “Many chronic pain sufferers are seeking a non-opioid treatment that offers relief.
  • Based on findings to date, we believe SP-26 has the potential to be the first at-home approved ketamine treatment for chronic pain including fibromyalgia.”

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Retrieved on: 
Tuesday, November 21, 2023

ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Key Points: 
  • “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
  • Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia.
  • The drug dispersion through the nose to brain has been designed to optimize patient safety and therapeutic delivery.

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, November 8, 2023

ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range.
  • In collaboration with AmplifyBio, Silo Pharma’s contract research organization (CRO) partner, the six- to eight-week non-good laboratory practice (GLP) study will include single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study.
  • “Determining the dose range that should be studied is an important step before taking a new drug candidate into a first-in-human trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Retrieved on: 
Monday, October 16, 2023

ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).

Key Points: 
  • SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
  • “The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects.
  • In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated.

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

Retrieved on: 
Wednesday, October 11, 2023

ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.

Key Points: 
  • ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a human factor study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD).
  • The study will evaluate the human factor interface and usability of SPC-15’s intranasal formulation in combination with a nose-to-brain delivery mechanism.
  • “The human factors study is an important step as we prepare and plan to enter the clinic with SPC-15 for the treatment of PTSD and stress-related disorders,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University pursuant to a sponsored research agreement and option.